Semin Thromb Hemost 2011; 37(5): 607-614
DOI: 10.1055/s-0031-1281050
© Thieme Medical Publishers

Diagnosis and Management of von Willebrand Disease in China

Jianhui Xu1 , Zhiqiang Yu2 , Lei Zhang1 , Changgeng Ruan2 , Renchi Yang2
  • 1State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Peoples Republic of China
  • 2Jiangsu Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, Peoples Republic of China
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. November 2011 (online)

Zoom Image

ABSTRACT

In China, the care of patients with a bleeding disorder is not organized into designated centers with a national protocol. However, currently developed organizations of hematologists and hemophilia patients are beginning to ensure better diagnosis, treatment, and care of affected patients. The diagnosis of von Willebrand disease (VWD) in China is still at an early stage. Misdiagnosis of the disease is difficult to avoid, and there is a need to improve our current diagnostic strategy. Our data show that assessment of von Willebrand factor (VWF) antigen levels is pivotal in ranking VWD clinical severity for replacement therapy. Treatment choices for VWD in China are currently limited to replacement therapy and antifibrinolytic drugs. Most VWD patients in China do not need replacement therapy. New phenotypic assays and genetic testing of VWF for research purposes have developed with results published in the Chinese medical literature in the last few years, and many are practical and feasible for diagnostic application. However, more efforts are needed for their widespread use for precise VWD diagnosis in China.